Gator Bio, Inc. | June 02, 2022
Gator Bio, the next gen Biolayer Interferometry solutions company, has signed an agreement with I&L Biosystems GmbH, a distributor of innovative biomedical technology and products. The agreement will allow Gator Bio to expand rapidly its product offerings into the European Union, a key region for Gator's growth strategy as it begins its global reach.
I&L Biosystems has a history of bringing new and innovative technologies into market — as evidenced by its previous success in commercializing e.g., various multi-analyzer, protein purification devices, SPR instruments, and bioreactors, etc. We look forward to working with the I&L team to bring the Gator platform to users throughout the region, helping meet the demand for therapeutics development and manufacturing."
Dr. Hong Tan, CEO of Gator Bio.
Gator BLI platform and a range of innovative biosensors are an important addition to I&L's portfolio of protein characterization products, and we are very excited about the possibilities the Gator shall give our customers in characterizing antibodies, AAVs and small molecule drugs, Access to this next gen technology is key to the continued enablement of our biopharma and academia research customers across our geographies. We are very excited about helping research and manufacturing community with the novel applications in gene therapy, immune therapy and lipid nano particle development."
Mr. Alexander M. Beljaars, CEO of I&L Biosystems GmbH.
The latest partnership of two companies builds on Gator Bio's commitment to providing high-quality BLI platforms globally, recently demonstrated through a strategic partnership with BMS Korea (Bio Medical Sciences) to provide sales and services to biotherapeutics and gene therapy companies in Republic of Korea.
About Gator Bio, Inc.
Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. Gator Bio along with its sister company ET Healthcare are part of Access Medical Systems. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration and epitope binning, etc. Most importantly, Gator Bio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China.
About I&L Biosystems
I&L Biosystems is a leading distributor of innovative scientific products with the headquarter in Königswinter, Germany. The company was founded in 1991 and has been growing steadily ever since. The focus of I&L is on sales and distribution of high-quality laboratory equipment to customers and researchers in the microbiology, cell biology and biotechnology markets in almost all European countries. High quality of the products, competent advice and fast service are the basis for a long-lasting relationship with our customers and partners in industry, research and development. More than 120 employees ensure that our customers throughout Europe receive excellent support for technical or application-related questions.
ProteoNic | October 20, 2020
ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of specified proprietary products from mammalian cells. Financial details of the agreement were not disclosed. ProteoNic's protein expression technology improves production levels across a range of host cells, selection systems and protein targets. It increases transcription and translation rates via a combination of novel genetic elements, which together exert a powerful positive effect on recombinant protein production levels without impacting product quality or cell line stability attributes. 2G UNic™ can be readily combined with other protein expression-enhancing technologies to improve their performance.
Mission Bio | March 15, 2022
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced new findings by Daniel Snellings from the lab of Douglas Marchuk, PhD, at Duke University School of Medicine using single-cell DNA sequencing to identify genetic mechanisms leading to the development of cerebral cavernous malformations (CCMs). The study, published today in the journal Nature Cardiovascular Research, is the latest demonstration of how Mission Bio's Tapestri Platform is allowing researchers to probe new aspects of biology at a single-cell resolution not possible with bulk sequencing. Dr. Marchuk is Professor of Molecular Genetics and Microbiology at Duke.
CCMs, a blood vessel abnormality that can lead to brain hemorrhages, have long been associated with developmental venous anomalies (DVAs), a typically benign but irregular vascular arrangement often found near sporadic CCMs – though researchers had yet to prove a link. In the paper, Snellings and colleagues sequenced DNA from three CCM patient samples to see if somatic mutations in MAP3K3 or PIK3CA – common in patients with CCMs – co-existed in the same cells. Single-cell DNA sequencing with Tapestri found co-occurring mutations in the cells of all three samples, a pattern that could not be determined by bulk sequencing. Further, the group found that the CCMs and the associated DVAs harbored identical mutations in PIK3CA, but that mutations in MAP3K3 were only found in the CCMs. Because of the pattern of PIK3CA and MAP3K3 co-occurrence in CCMs, the team could assess the temporal pattern of genetic mutations associated with disease progression. They determined that DVA is the first lesion to occur, and that CCM development happens only after acquisition of an activating MAP3K3 mutation in a cell of the existing DVA.sazsz
It was surprising to find that something as common as DVAs—which are present in up to 16% of people—could be caused by a cancer driver mutation. This explains why sporadic CCMs are often found in the vicinity of a DVA, and may explain why other diseases like pontine gliomas are also found near DVAs."
Tapestri is regularly deployed in cancer research to detect somatic mutations in clonal populations as a way of tracking tumor development, and the researchers adapted that methodology to evaluate the relationship between DVAs and CCMs. Since DVAs are not regularly biopsied, the researchers also confirmed the presence of circulating mRNAs in patients with both CCM and DVA related to this biological pathway, in plasma – a first step toward establishing a biomarker for CCM risk in patients with DVAs.
We expect this research will have a meaningful impact for patients at risk for developing spontaneous cerebral cavernous malformations, which can lead to strokes or even death, This paper is a powerful new demonstration that there are many disease areas where single-cell DNA sequencing is helping elucidate the mechanisms of disease development, and identifying potential targets for diagnostics or therapeutics."
Yan Zhang, PhD, CEO of Mission Bio.
About Mission Bio
Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio's multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.
The company's Tapestri platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer.